94.17 0.00 (0.00%)
After hours: 5:57PM EST
|Bid||0.00 x 800|
|Ask||96.38 x 900|
|Day's Range||93.61 - 95.59|
|52 Week Range||69.35 - 96.57|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||39.65|
|Earnings Date||Feb 13, 2019 - Feb 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||101.09|
The best pharmaceutical stocks to buy have a commonality: Strong Composite Ratings and Relative Strength Ratings.
Eli Lilly is the IBD Stock Of The Day as the Big Pharma giant approaches a buy point on excitement for its diabetes treatments.
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Zoetis (ZTS).
To receive further updates on this Zoetis Inc. (NASDAQ:ZTS) trade as well as an alert when it’s time to take profits, sign up for a risk-free trial of Power Options Weekly today. This morning I am recommending a bullish trade on Zoetis (NYSE:ZTS), a $44.5 billion company that discovers, develops, manufactures, and sells animal health medicines and vaccines.
Zoetis (ZTS) beats both earnings and sales estimates in the third quarter of 2018. The company also updates its 2018 outlook.
Technology stocks outperformed again Thursday. Top stocks today included semiconductor stocks like Applied Materials and Lam Research.
Investing.com - Zoetis Inc (NYSE:ZTS) reported third quarter earnings that beat analyst's expectations on Thursday and revenue that topped forecasts.
The Parsippany, New Jersey-based company said it had profit of 71 cents per share. Earnings, adjusted for costs related to mergers and acquisitions and non-recurring costs, were 83 cents per share. The ...
Short interest is extremely low for ZTS with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ZTS. The net inflows of $385 million over the last one-month into ETFs that hold ZTS are among the lowest of the last year and appear to be slowing.
Zoetis Inc. (ZTS) will participate in the Credit Suisse 27th Annual Healthcare Conference on Tuesday, Nov. 13, 2018, in Scottsdale, Ariz. Glenn David, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services.
Zoetis' (ZTS) diversified product portfolio, global footprint and productive R&D should help drive both top-and bottom-line growth in the third quarter of 2018.
Short interest is extremely low for ZTS with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ZTS. The $2.29 billion in inflows that ETFs holding ZTS received over the last one-month is a decline from earlier in the period and among the weakest of the past year.
NEW YORK, Oct. 24, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.